In the December 2017 issue of Cancer Biotherapy and Radiopharmaceuticals (vol. 32, no. 10, page 387), there were errors requiring correction in the retraction notice entitled, Tumor Protein D52-Like 2 Contributes to Proliferation of Breast Cancer Cells; 10.10.89/cbr.2014.1723.
List of corrected text in this retraction:
Original retraction text: …the investigator discovered that the lentiviral sequence cited to target TPD52L2 actually does not correspond to any TPD52L2 sequence, and does not show homology to any sequence in the non-redundant nucleotide database (as per a Blastn search conducted by the investigator).
CORRECTED text: …the investigator discovered that the lentiviral sequence cited to serve as a “non-silencing” control in fact shows homology to the human TPD52L2 gene (as per a Blastn search conducted by the investigator).
Original retraction text: The investigator claimed that the article reported using the 5'-GCGG… shRNA as a non-targeting control, but the alternative “TPD52L2-targeting” 5'-CCGG… shRNA does not target the TPD52L2 gene as described, or any other sequence in the non-redundant nucleotide database.
CORRECTED text: The investigator claimed that the article therefore reported the results of knocking down the TPD52L2 gene as both the gene of interest and the supposed negative control.
Original retraction text: The investigator's concern was such that since the article did not employ a lentiviral construct targeting the TPD52L2 gene, the experimental results reported must be invalid.
CORRECTED text: The investigator's concern was such that since the article employed an incorrect control lentiviral construct, the experimental results reported must be invalid.
The online version of the retraction notice has been corrected to reflect this change.